Condition
Metastatic Liver Carcinoma
Total Trials
5
Recruiting
2
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 1 (2)
Trial Status
Active Not Recruiting2
Recruiting2
Terminated1
Clinical Trials (5)
Showing 5 of 5 trials
NCT06349642Recruiting
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
NCT03028311Phase 1Active Not RecruitingPrimary
Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer
NCT04785287Phase 1Terminated
Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies
NCT03823144Not ApplicableRecruiting
Intravital Microscopy in Human Solid Tumors
NCT05038254Not ApplicableActive Not Recruiting
Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events
Showing all 5 trials